Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
about
High-throughput sequencing identifies STAT3 as the DNA-associated factor for p53-NF-kappaB-complex-dependent gene expression in human heart failureGREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancerZNF703 gene amplification at 8p12 specifies luminal B breast cancerEstrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAsPrognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-betHistone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRMCooperating transcription factors mediate the function of estrogen receptorMechanisms and therapeutic advances in the management of endocrine-resistant breast cancerThe p53-estrogen receptor loop in cancerGene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesPrior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast CancerCistrome plasticity and mechanisms of cistrome reprogrammingA genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in JapaneseThe HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway.Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue.A reason why the ERBB2 gene is amplified and not mutated in breast cancer.Genetic variation of clock genes and cancer risk: a field synopsis and meta-analysisTranslating extranuclear steroid receptor signaling to clinical medicine.Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complexRaf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cellsInference of hierarchical regulatory network of estrogen-dependent breast cancer through ChIP-based data.Global characterization of transcriptional impact of the SRC-3 coregulatorGlobal analysis of estrogen receptor beta binding to breast cancer cell genome reveals an extensive interplay with estrogen receptor alpha for target gene regulationMM-ChIP enables integrative analysis of cross-platform and between-laboratory ChIP-chip or ChIP-seq dataRegulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor.Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells.Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer.Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.PBX1 genomic pioneer function drives ERα signaling underlying progression in breast cancer.Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistanceRelevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer.Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.Nuclear receptor modulation--role of coregulators in selective estrogen receptor modulator (SERM) actions.Integrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression.Bioinformatic analysis of cis-regulatory interactions between progesterone and estrogen receptors in breast cancer.Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
P2860
Q21183975-66C735E4-62FA-4082-8F6E-8C763CFAFE25Q21560759-E9857D6F-FEEB-491D-AC67-439C5E9ECBBEQ24293333-E6A8D1C7-59B4-40AA-A247-292163F8FDBFQ24631037-703EBA34-14FF-4585-A59E-2C410B1F6A39Q24645449-021F3477-D8DC-412D-B033-89962FFC94EEQ24653898-5E447245-7644-4AF2-9DA0-6F7F553BDFDEQ26996464-2CDEE491-5409-40C6-8645-6CCE28FD9DB1Q27001260-5F0C704F-711F-442C-B35A-CBB8AC7D479CQ27027865-77D2F35F-63E1-40A1-9D4A-3E7E955B347AQ28548165-E6BB03EE-201E-4B25-BF3B-BFE67C579B04Q28550645-26BF1C2E-DB24-4020-8143-9CB3DE2A4DA7Q28727255-357C0F57-66C8-46FE-B83D-078D16BB71CFQ28943542-532F5BC4-085D-4177-AE8E-2FBD4D961CF2Q30425478-31FEEE22-38C6-437E-9869-9264C7212207Q31134061-CFC26980-4235-4A70-8F63-D8EF7E05A300Q33410385-F7278ADD-E740-4209-A095-C885505B8EA2Q33618941-36FFBC11-3B4D-4D68-8159-942533BDF341Q33692847-A160EBC4-F774-48D3-A1DC-37717843FB15Q33701396-2E532F75-F952-4184-B76D-06EBBECADFF6Q33759701-606E0C09-9DEC-42F6-897C-7C64A5596999Q33774643-05B0B6C4-6FD8-414F-B53A-EB60ADE74CD4Q33780217-428F322F-D7E6-4089-9ED1-4A8FD48D1075Q33793540-7487B510-D1BA-4AB6-8764-5F380B048149Q33809896-5E5D3F8B-38D3-4B3D-8B9E-0D1255F1B5E6Q33853085-0BB47C05-7607-46CB-9B34-FEB16E8A3730Q33874323-77FE64EB-EA92-436B-87BE-D6DC7AFFA7ABQ33945493-BD002923-2A78-480E-8CDA-F4772CF241CBQ34031831-E814D827-02EF-4F62-B573-9338123042E0Q34077845-C4472466-E4A4-4206-81EF-7EA3AC4F8D82Q34085622-2BBD5776-F493-4B0A-B4DF-5EC2EA30D0ABQ34164930-A59EFF7D-D5D7-4B7C-9A93-BECDE46F2881Q34255976-EAB1633F-477B-4D0A-8A51-10E5C9431E16Q34286419-8E450781-979C-4329-BB79-D48DFF250478Q34306286-A1FC0416-9774-4407-B5F8-2700F7FC1EBFQ34311300-59046DD3-9ED6-4019-A339-B9A88BA95461Q34315391-EF8E4295-7BBE-4988-8EEA-CAEAB00EE3DBQ34493813-F82F9B3A-8A6B-40A1-8E2E-8BC9A45C4745Q34568706-C9E39CC2-C4C6-4838-98CB-C671855C50DAQ34747157-48D1074C-00CF-4912-88BC-07E1310B204FQ35051765-951BF87A-BFA7-4415-B8A6-A128FE09FD1E
P2860
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@ast
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@en
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@nl
type
label
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@ast
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@en
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@nl
prefLabel
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@ast
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@en
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@nl
P2093
P2860
P3181
P356
P1433
P1476
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen
@en
P2093
Iain R Hutcheson
Jason S Carroll
Kelly A Holmes
Robert I Nicholson
Timothy R Geistlinger
William J Howat
P2860
P2888
P3181
P356
10.1038/NATURE07483
P407
P577
2008-12-04T00:00:00Z
P5875
P6179
1047594933